Pharmacyclics, Inc. (PCYC) Files sNDA for IMBRUVICA
- Rite Aid (RAD) Tops Q2 EPS by 7c; Cuts FY15 EPS Outlook
- Pre-Open Stock Movers 9/18: (EMKR) (XXII) (VVUS) Higher; (FLXN) (RAD) (PIR) Lower (more...)
- Apple (AAPL) Gets One Step Closer to Starting iPhone 6/6+ Sales in China
- Initial Jobless Claims Rose to 280K Last Week, Coming in Below Expectations
- UPDATE: U.S. Housing Starts Miss Expectations at 956K in August (XHB)
Pharmacyclics, Inc. (NASDAQ: PCYC) announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), based on data from the randomized, multi-center, open-label Phase III RESONATETM study, PCYC-1112, a head-to-head comparison of single agent IMBRUVICATM (ibrutinib) versus ofatumumab in 391 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who had received at least one prior therapy. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
At a planned interim analysis in January 2014, the results of the RESONATE study demonstrated a statistically significant improvement in progression-free survival, the primary endpoint of the study, in patients treated with IMBRUVICA. Further, patients in the IMBRUVICA arm also showed a statistically significant improvement in overall survival, a key secondary endpoint of the trial. The safety profile of IMBRUVICA was acceptable and showed a favorable risk benefit profile. Data from this study will be discussed in a presentation at the 50th annual meeting of the American Society of Clinical Oncology in Chicago, May 30 – June 3, 2014.
You May Also Be Interested In
- Neogen Corp (NEOG) Enters Marketing Agreement with Merck (MRK) for Igenity Dairy Heifer Program
- USEC (USU) Plans Emergence from Chapter 11 on Sept. 30th
- WPCS Int'l (WPCS) Pleads with Investors for Share Increase; Sends Letter
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot Corp. News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!